Evidence map›Paper›PMID 37047613›Full record

ArticleInternational journal of molecular sciences2023

Intrinsic Permeation and Anti-Inflammatory Evaluation of Curcumin, Bisdemethoxycurcumin and Bisdemethylcurcumin by a Validated HPLC-UV Method.

Helen-Lissette Alvarado, David Limón, Ana-Cristina Calpena-Campmany, Mireia Mallandrich, Laura Rodríguez-Cid, Núria Aliaga-Alcalde, Arántzazu González-Campo, Lluïsa Pérez-García

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. EnhancedRSC advances · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Helen-Lissette AlvaradoDepartament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII 27-31, 08028 Barcelona, Spain.
David LimónInstitut de Nanociència i Nanotecnologia (IN2UB), Universitat de Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0002-8556-5531
Ana-Cristina Calpena-CampmanyDepartament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII 27-31, 08028 Barcelona, Spain.ORCID 0000-0002-4989-4821
Mireia MallandrichDepartament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII 27-31, 08028 Barcelona, Spain.ORCID 0000-0001-9316-8459
Laura Rodríguez-CidInstitute of Materials Science of Barcelona (ICMAB-CSIC), Campus of the Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Núria Aliaga-AlcaldeInstitute of Materials Science of Barcelona (ICMAB-CSIC), Campus of the Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Arántzazu González-CampoInstitute of Materials Science of Barcelona (ICMAB-CSIC), Campus of the Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.ORCID 0000-0002-1209-8119
Lluïsa Pérez-GarcíaInstitut de Nanociència i Nanotecnologia (IN2UB), Universitat de Barcelona (UB), 08028 Barcelona, Spain.
Institut de Nanociència i Nanotecnologia de la Universitat de BarcelonaUniversitat Autònoma de Barcelona · ESInstitució Catalana de Recerca i Estudis Avançats · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin shows anti-inflammatory activity, and it has been widely investigated for neurodegenerative diseases, adjuvant treatment in AIDS and antitumor activity against different tumors, among other activities. The goal of this work was to evaluate the capacity of curcumin and its derivatives (bisdemethoxycurcumin and bisdemethylcurcumin) in preventing the irritant effects of topically applied xylol and to assess the intrinsic capacity of curcuminoids in permeating human skin by ex vivo permeation tests. Its secondary goal was to validate an HPLC method to simultaneously determine the curcuminoids in the samples from the ex vivo permeation studies and drug extraction from the skin. Curcuminoid quantification was performed using an RP-C18 column, at isocratic conditions of elution and a detection wavelength of 265 nm. The method was specific with a suitable peak resolution, as well as linear, precise, and accurate in the range of 0.195-3.125 μg/mL for the three curcuminoids. Bisdemethylcurcumin showed the greatest permeation through the human skin, and it was the curcuminoid that was most retained within the human skin. The anti-inflammatory activity of the curcuminoids was evaluated in vivo using a xylol-induced inflammation model in rats. Histological studies were performed to observe any changes in morphology at the microscopic level, and these three curcuminoids were found to be respectful within the skin structure. These results show that these three curcuminoids are suitable for anti-inflammatory formulations for dermal applications, and they can be properly quantified using HPLC-UV.

Indexed as

CurcuminAnimalsAnti-Inflammatory AgentsChromatography, High Pressure LiquidCurcumaDiarylheptanoidsHumansRatsAnti-Inflammatory AgentsCurcuminDiarylheptanoidsanti-inflammatorybisdemethoxycurcuminbisdemethylcurcumincurcumincurcuminoidshistologyHPLCintrinsic ex vivo permeationmethod validation

Identifiers

PMID37047613
PMCPMC10095365
OpenAlexW4362583364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.